10-Q: Nika Pharmaceuticals Q1 2026 Financials Show Continued Net Loss

Nika Pharmaceuticals, Inc. reported its Q1 2026 financial results, detailing a net loss and ongoing reliance on related party financing, while also highlighting strategic agreements and operational developments.

Summary

• Nika Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $13,359 for the three months ended March 31, 2026, compared to a net loss of $12,945 for the same period in 2025.
• Total operating expenses for Q1 2026 were $13,359, an increase from $12,945 in Q1 2025.
• General and administrative expenses increased to $2,639 in Q1 2026 from $1,800 in Q1 2025.
• Professional fees decreased slightly to $10,720 in Q1 2026 from $11,145 in Q1 2025.
• Net cash used in operating activities was $13,359 for Q1 2026, compared to $12,945 for Q1 2025.
• The company received $13,000 in loan proceeds from related parties in Q1 2026, down from $30,000 in the prior year period.
• The company has an accumulated deficit of $9,017,368 as of March 31, 2026, and has generated no income to date, raising substantial doubt about its ability to continue as a going concern.
• The company is exploring capital raising through equity or debt securities, or borrowings.
• Disclosure controls and procedures were found to be not effective due to a lack of an audit committee and separation of duties.
• The company has entered into various agreements, including exclusive rights agreements for TNG, Carotilen, and Physiolong, and a joint business agreement for IPF platform medicinal products.
• Recent developments include the acquisition and subsequent cancellation of Nika Pharmaceuticals, Ltd., and a production agreement with Nika Europe, Ltd. for ITV-1.
• A consultancy agreement was signed with MD Global Partners, LLC for capital raising and growth initiatives.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, lack of revenue, and significant going concern issues, despite some positive strategic developments.

Positives

• The company has secured exclusive rights agreements for the production and distribution of TNG, Carotilen, and Physiolong, indicating strategic expansion into new product areas.
• A joint business agreement with Immunotech Laboratories BG, Ltd. aims to develop and distribute medicinal products based on the Inactivated Pepsin Fraction (IPF) platform, leveraging existing U.S. patents.
• The company has acquired four technologies for generic drugs and a dietary supplement, expanding its product pipeline.
• A production agreement with Nika Europe, Ltd. for ITV-1 is in place, with Nika Europe to organize and bear production costs while Nika Pharmaceuticals expects a profit of $1,120 per set.
• The company's common stock was uplisted to OTCQB on December 9, 2024.
• A consultancy agreement with MD Global Partners, LLC was signed on March 5, 2026, to assist with capital raising and growth initiatives.

Negatives

• The company incurred a net loss of $13,359 for the three months ended March 31, 2026, and $12,945 for the same period in 2025.
• The company has an accumulated deficit of $9,017,368 as of March 31, 2026, and has generated no income to date.
• The company relies on related party non-interest bearing loans to cover operating expenses, raising substantial doubt about its ability to continue as a going concern.
• Disclosure controls and procedures were found to be not effective due to a lack of an audit committee and separation of duties.
• The company's cash balance has decreased from $1,889 at December 31, 2025, to $1,530 at March 31, 2026.
• Loans from related parties decreased to $13,000 in Q1 2026 from $30,000 in Q1 2025.

Risks

• The company's accumulated deficit and lack of income raise substantial doubt about its ability to continue as a going concern.
• The company relies on related party non-interest bearing loans for operating expenses.
• Disclosure controls and procedures are not effective due to a lack of an audit committee and separation of duties, which could lead to material misstatements.
• The company's ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
• Factors which could have a material adverse effect on operations and future prospects include changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, and competition.

Future Outlook

The company's future outlook is uncertain due to its ongoing net losses and reliance on related party financing. However, the company is actively pursuing capital raising efforts and has entered into strategic agreements and consultancy services to support growth initiatives and potential transactions. The completion of the pharmaceutical factory construction and the production of ITV-1 are key future operational milestones.

Management Comments

• The company's disclosure controls and procedures were not effective for the quarterly period ended March 31, 2026, due to a lack of an audit committee and separation of duties.
• Management believes that the company will continue as a going concern, potentially through raising additional capital via equity or debt securities, or borrowings.
• The company has no revenue and relies on related party non-interest bearing loans to pay for its operating expenses, which raises substantial doubt about its ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Nika Pharmaceuticals operates in a highly competitive and capital-intensive pharmaceutical and biotechnology sector. The company's focus on niche products like TNG and dietary supplements, alongside potential generic drug technologies, positions it in a segment that requires significant R&D investment and regulatory navigation. The reliance on related party financing and the ongoing net losses are common challenges for early-stage or development-focused biotech firms, but the recent uplisting to OTCQB and the engagement of a consultancy for capital raising suggest efforts to secure external funding and improve market visibility.

Comparison to Industry Standards

• Companies in the pharmaceutical and biotechnology sector typically aim for revenue generation through product sales, licensing agreements, or successful clinical trial outcomes. Nika Pharmaceuticals currently reports no revenue, which is a significant deviation from industry standards for established players.
• The significant accumulated deficit ($9,017,368) and net losses are common for companies in the R&D phase, but sustained losses without clear revenue streams can be a concern compared to companies with approved products generating sales.
• Reliance on related party financing is not uncommon for early-stage companies, but established pharmaceutical firms typically access a broader range of funding sources, including venture capital, public markets, and strategic partnerships.
• The lack of effective disclosure controls and procedures, specifically the absence of an audit committee and separation of duties, is a governance concern that deviates from best practices observed in larger, more established pharmaceutical companies.

Corporate Governance

Legal Proceedings

• There are no legal proceedings against the Company, and the Company is unaware of any proceedings contemplated against it.

Related Party Transactions

• Nika Europe, Ltd. advanced the Company $13,000 for general operating expenses during the period ended March 31, 2026. The total amount due to Nika Europe is $92,460.
• Dimitar Slavchev Savov advanced the Company $205,164 as of March 31, 2026, for general operating expenses.
• Nika Pharmaceuticals LTD advanced the Company $34,000 during the year ended December 31, 2024, for general operating expenses. The total amount due to Nika Pharmaceuticals LTD is $34,000 as of March 31, 2026.
• Exclusive Rights Agreement with VITAL FE Joint Stock Company (VITAL) for TNG, where Dimitar Savov is a 70% owner of VITAL. The company issued 8,000,000 shares of Preferred stock to be issued in the name of Dimitar Slavchev Savov.
• Exclusive Rights Agreement with MICAR 11 LTD. for Carotilen and Physiolong, where Dimitar Savov is the 100% owner of MICAR. The company issued 2,000,000 shares of Preferred stock to be issued in the name of Dimitar Slavchev Savov.
• Exclusive Rights Agreement with Dimitar Slavchev Savov for production and sale of six dietary supplements.
• Joint Business Agreement with Immunotech Laboratories BG, Ltd., where Dimitar Slavchev Savov owns 51% and is the general manager.
• Acquisition of four technologies from AIPFPCB, with the cost paid by Dimitar Slavchev Savov.
• Supply Agreement with Shanghai Marya Pharmaceutical Engineering & Project Co., Ltd. for vial production line equipment, with an initial down payment made by Dimitar Savov.
• Non-monetary in-kind contribution of a production building and land by Nika Pharmaceuticals, Ltd. (wholly owned by Dimitar Savov at the time) to Nika Europe, Ltd.
• Cancellation of the acquisition of Nika Pharmaceuticals, Ltd. from Dimitar Slavchev Savov.
• Production agreement with Nika Europe, Ltd. for ITV-1, where Nika Europe is organized and costs borne by Nika Europe, and Nika Pharmaceuticals receives expected profit.

Stakeholder Impact

• Shareholders: The continued net losses and going concern issues may negatively impact shareholder value. However, strategic agreements and potential capital raises could offer future upside.
• Creditors: The company's reliance on related party loans and its going concern status could pose risks to non-related party creditors.
• Employees: The company's financial instability could create uncertainty for employees regarding job security and future growth.
• Management: Management is facing challenges related to financial performance, operational execution, and corporate governance deficiencies.

Next Steps

• Continue efforts to raise additional capital through equity, debt, or borrowings.
• Complete the construction of the pharmaceutical factory in Bulgaria.
• Proceed with the production of ITV-1 under the agreement with Nika Europe, Ltd.
• Implement improvements to disclosure controls and procedures, including establishing an audit committee and ensuring separation of duties.
• Continue to develop and commercialize products based on acquired technologies and existing agreements.

Key Dates

Recommendation

The company exhibits significant financial distress with ongoing net losses and substantial doubt about its ability to continue as a going concern. However, the strategic agreements for product development and distribution, the uplisting to OTCQB, and the engagement of a consultancy for capital raising indicate potential for future recovery and growth. A 'hold' recommendation reflects the balance between these significant risks and speculative opportunities, pending clearer signs of financial stabilization and revenue generation.

Keywords

Nika Pharmaceuticals, Form 10-Q, Quarterly Report, Financial Statements, Net Loss, Going Concern, Related Party Transactions, Pharmaceuticals, Biotechnology, SEC Filing